Form 4: Lucid Diagnostics Director Dennis Matheis Acquires Stock Options

Director Dennis Matheis acquired employee stock options in Lucid Diagnostics Inc. on May 8, 2024.

Summary

• On May 8, 2024, Dennis Matheis, a director of Lucid Diagnostics Inc., acquired 241,500 employee stock options.
• The exercise price of these options is $1.03.
• One third of the options vest on December 31, 2024, with the remainder vesting in eight equal quarterly installments starting March 31, 2025.
• The options expire on May 8, 2034.
• Following the transaction, Matheis directly owns 241,500 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither inherently positive nor negative.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance beyond the vesting schedule of the options.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It provides transparency into the incentives provided to company directors.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates